Covered recipient · General Payments record
ROBERT A DICHMANN
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$104.19
8 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $90.73 | 7 |
| Education | $13.46 | 1 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Astellas Pharma US Inc | $20.50 | 1 |
| Janssen Biotech, Inc. | $15.31 | 1 |
| Pharmacyclics LLC, An AbbVie Company | $14.32 | 1 |
| E.R. Squibb & Sons, L.L.C. | $13.92 | 1 |
| GlaxoSmithKline, LLC. | $13.84 | 1 |
| Merck Sharp & Dohme Corporation | $13.46 | 1 |
| PFIZER INC. | $12.84 | 2 |
Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ROBERT A DICHMANN
NPI 1245232578 · CMS profile ID 328270
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
SANTA MARIA, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1245232578?year=2020&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ROBERT A DICHMANN, NPI 1245232578, CMS profile ID 328270. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1245232578?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). ROBERT A DICHMANN, NPI 1245232578, CMS profile ID 328270. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1245232578?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- ROBERT A DICHMANN, NPI 1245232578, CMS profile ID 328270, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1245232578?year=2020&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
8 matching records · $104.19 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–8 of 8.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corporation | $13.46 | 10/20/2020 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747768585 | CMS |
| GlaxoSmithKline, LLC. | $13.84 | 09/17/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738924171 | CMS |
| Astellas Pharma US Inc | $20.50 | 02/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 718316475 | CMS |
| E.R. Squibb & Sons, L.L.C. | $13.92 | 02/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727790971 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $14.32 | 02/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725661771 | CMS |
| PFIZER INC. | $0.14 | 01/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743630553 | CMS |
| PFIZER INC. | $12.70 | 01/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743707807 | CMS |
| Janssen Biotech, Inc. | $15.31 | 01/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719379817 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $5,981.45 | 2 |
| PY2024 | Principal investigator | $7,185.45 | 2 |
| PY2023 | Principal investigator | $33,549.76 | 11 |
| PY2022 | Principal investigator | $162,021.03 | 21 |
| PY2021 | Principal investigator | $97,528.06 | 21 |
| PY2020 | Principal investigator | $227,117.30 | 35 |
| PY2019 | Principal investigator | $393,411.87 | 53 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
53 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $661.72 | 12/31/2019 | Non-covered Recipient Entity Translational Research In Oncology- | A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care | No dispute reported | 06/30/2026 | 684993973 |
| Principal investigator 1 | AstraZeneca UK Limited | $262.33 | 12/31/2019 | Non-covered Recipient Entity Translational Research In Oncology- | This is a randomized open label multi center global Phase III study to determine the efficacy and safety of MEDI4736 as monotherapy and MEDI4736 tremelimumab combination therapy versus SoC therapy in the target patient population | No dispute reported | 06/30/2026 | 685001703 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $7,650.00 | 12/27/2019 | Non-covered Recipient Entity Translational Research In Oncology- | A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care | No dispute reported | 06/30/2026 | 684993897 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $8,511.80 | 12/13/2019 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY US INC | ABT 199 GDC 0199 IN 1L DLBCL | No dispute reported | 06/30/2026 | 681065823 |
| Principal investigator 1 | PFIZER INC. | $100.00 | 11/14/2019 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY US INC | MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT PD0332991 PALBOCICLIB GOSERELIN IN WOMEN WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY | No dispute reported | 06/30/2026 | 671657189 |
| Principal investigator 1 | Seattle Genetics, Inc. | $400.00 | 10/18/2019 | Non-covered Recipient Entity CENTRAL COAST MEDICAL ONCOLOGY | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | No dispute reported | 06/30/2026 | 709079149 |
| Principal investigator 1 | Seattle Genetics, Inc. | $1,098.00 | 10/09/2019 | Non-covered Recipient Entity CENTRAL COAST MEDICAL ONCOLOGY | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | No dispute reported | 06/30/2026 | 709079145 |
| Principal investigator 1 | Seattle Genetics, Inc. | $4,224.00 | 10/09/2019 | Non-covered Recipient Entity CENTRAL COAST MEDICAL ONCOLOGY | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | No dispute reported | 06/30/2026 | 709079147 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $8,535.00 | 09/12/2019 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY US INC | ABT 199 GDC 0199 IN 1L DLBCL | No dispute reported | 06/30/2026 | 681064761 |
| Principal investigator 1 | PFIZER INC. | $50.00 | 07/30/2019 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY US INC | MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT PD0332991 PALBOCICLIB GOSERELIN IN WOMEN WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY | No dispute reported | 06/30/2026 | 671657187 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $11,866.50 | 07/26/2019 | Non-covered Recipient Entity CENTRAL COAST MEDICAL ONCOLOGY | RIBOCICLIB STANDARD ENDOCRINE THERAPY IN PATIENTS WITH HR HER2 EARLY BC AT HIGH AMP INTERMEDIATE RISK FOR RECURRENCE | No dispute reported | 06/30/2026 | 640712837 |
| Principal investigator 1 | Seattle Genetics, Inc. | $3,901.00 | 07/22/2019 | Non-covered Recipient Entity CENTRAL COAST MEDICAL ONCOLOGY | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | No dispute reported | 06/30/2026 | 678824779 |
| Principal investigator 1 | Seattle Genetics, Inc. | $6.00 | 07/02/2019 | Non-covered Recipient Entity CENTRAL COAST MEDICAL ONCOLOGY | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | No dispute reported | 06/30/2026 | 678824775 |
| Principal investigator 1 | Seattle Genetics, Inc. | $21.00 | 07/02/2019 | Non-covered Recipient Entity CENTRAL COAST MEDICAL ONCOLOGY | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | No dispute reported | 06/30/2026 | 678824777 |
| Principal investigator 1 | Amgen Inc. | $158.00 | 06/22/2019 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY US INC | P3 Adjuvant Breast Cancer | No dispute reported | 06/30/2026 | 675794567 |
| Principal investigator 1 | AstraZeneca UK Limited | $3,310.00 | 06/03/2019 | Non-covered Recipient Entity Translational Research In Oncology- | This is a randomized open label multi center global Phase III study to determine the efficacy and safety of MEDI4736 as monotherapy and MEDI4736 tremelimumab combination therapy versus SoC therapy in the target patient population | No dispute reported | 06/30/2026 | 685001695 |
| Principal investigator 1 | Seattle Genetics, Inc. | $219.00 | 05/22/2019 | Non-covered Recipient Entity CENTRAL COAST MEDICAL ONCOLOGY | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | No dispute reported | 06/30/2026 | 678824767 |
| Principal investigator 1 | Seattle Genetics, Inc. | $842.00 | 05/22/2019 | Non-covered Recipient Entity CENTRAL COAST MEDICAL ONCOLOGY | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | No dispute reported | 06/30/2026 | 678824769 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,639.00 | 05/16/2019 | Non-covered Recipient Entity Translational Oncology Research International | Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices | No dispute reported | 06/30/2026 | 639763645 |
| Principal investigator 1 | Eli Lilly and Company | $2,509.00 | 05/14/2019 | Non-covered Recipient Entity TRANSLATIONAL ONCOLOGY RESEARCH INTERNATIONAL INC | A PHASE 1B OPEN-LABEL PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF FIRST-LINE METASTATIC PANCREATIC CANCER | No dispute reported | 06/30/2026 | 654298481 |
| Principal investigator 1 | PFIZER INC. | $50.00 | 05/02/2019 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY US INC | MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT PD0332991 PALBOCICLIB GOSERELIN IN WOMEN WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY | No dispute reported | 06/30/2026 | 671626043 |
| Principal investigator 1 | Seattle Genetics, Inc. | $10,610.00 | 05/01/2019 | Non-covered Recipient Entity CENTRAL COAST MEDICAL ONCOLOGY | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | No dispute reported | 06/30/2026 | 678824765 |
| Principal investigator 1 | Incyte Corporation | $1,280.00 | 04/29/2019 | Non-covered Recipient Entity CENTRAL COAST MEDICAL ONCOLOGY | PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES | No dispute reported | 06/30/2026 | 666475315 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 04/23/2019 | Non-covered Recipient Entity SANSUM CLINIC SANTA BARBARA | A Phase 2, Open Label, 2 Cohort Study of INCB050465, a PI3Kd Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor, CITADEL 204 | No dispute reported | 06/30/2026 | 666498911 |
| Principal investigator 1 | Seattle Genetics, Inc. | $9,435.00 | 04/18/2019 | Non-covered Recipient Entity CENTRAL COAST MEDICAL ONCOLOGY | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | No dispute reported | 06/30/2026 | 678824773 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $5,575.00 | 04/09/2019 | Non-covered Recipient Entity Translational Oncology Research International | Phase IIB 1L NSCLC Flat Dose Nivo Combo Schedule Safety | No dispute reported | 06/30/2026 | 639763653 |
| Principal investigator 1 | Eli Lilly and Company | $242.10 | 04/08/2019 | Non-covered Recipient Entity TRANSLATIONAL ONCOLOGY RESEARCH INTERNATIONAL INC | A PHASE 1B OPEN-LABEL PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF FIRST-LINE METASTATIC PANCREATIC CANCER | No dispute reported | 06/30/2026 | 654296479 |
| Principal investigator 1 | EMD Serono, Inc. | $285.00 | 03/26/2019 | Non-covered Recipient Entity UCLA TRIO US CAN CARE ASSOC MED GRP INC | EMR 100070-007 | No dispute reported | 06/30/2026 | 703032315 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,973.00 | 03/22/2019 | Non-covered Recipient Entity Translational Oncology Research International | A Phase IIIbIV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen | No dispute reported | 06/30/2026 | 639763635 |
| Principal investigator 1 | Amgen Inc. | $2,624.00 | 03/20/2019 | Non-covered Recipient Entity CENTRAL COAST MEDICAL ONCOLOGY GROUP | P3 Adjuvant Breast Cancer | No dispute reported | 06/30/2026 | 675784057 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $500.00 | 03/19/2019 | Non-covered Recipient Entity Translational Oncology Research International | A Phase IIIbIV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Renal Cell Carcinoma Who Have Progressed During or After Receiving One Prior Systemic Regimen | No dispute reported | 06/30/2026 | 639763639 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,795.68 | 03/14/2019 | Non-covered Recipient Entity Translational Research In Oncology- | A Phase III Randomized Open Label Multi Center Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum Based Chemotherapy in First Line Treatment of Patients with Advanced or Metastatic Non Small Cell Lung Cancer NSCLC MYSTIC | No dispute reported | 06/30/2026 | 684993893 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $4,485.00 | 03/07/2019 | Non-covered Recipient Entity Translational Oncology Research International | A Dose Frequency Optimization, Phase IIIBIV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mgkg or 240 mg Every | No dispute reported | 06/30/2026 | 639763641 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $58,060.30 | 03/06/2019 | Non-covered Recipient Entity Translational Oncology Research International | Phase III 1L Metastatic RCC Nivo Ipi Cabo | No dispute reported | 06/30/2026 | 708963897 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $500.00 | 03/05/2019 | Non-covered Recipient Entity Translational Oncology Research International | A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies | No dispute reported | 06/30/2026 | 639763637 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $42,014.50 | 03/05/2019 | Non-covered Recipient Entity Translational Oncology Research International | Phase IIIBIV Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previous Untreated, Advanced or Metastatic RCC | No dispute reported | 06/30/2026 | 639763647 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $929.67 | 02/25/2019 | Non-covered Recipient Entity Central Coast Medical Oncology Corporation | Phase IIB 1L NSCLC Flat Dose Nivo Combo Schedule Safety | No dispute reported | 06/30/2026 | 639763651 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $15,355.40 | 02/19/2019 | Non-covered Recipient Entity Translational Oncology Research International | Phase III Multiple Myeloma 3L Combo nivo - elo | No dispute reported | 06/30/2026 | 639763657 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 02/12/2019 | Non-covered Recipient Entity SANSUM CLINIC SANTA BARBARA | A Phase 2, Open Label, 2 Cohort Study of INCB050465, a PI3Kd Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor, CITADEL 204 | No dispute reported | 06/30/2026 | 666498937 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 02/12/2019 | Non-covered Recipient Entity SANSUM CLINIC SANTA BARBARA | A Phase 2, Open Label, 2 Cohort Study of INCB050465, a PI3Kd Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor, CITADEL 204 | No dispute reported | 06/30/2026 | 666498939 |
| Principal investigator 1 | Incyte Corporation | $6,000.00 | 02/12/2019 | Non-covered Recipient Entity SANSUM CLINIC SANTA BARBARA | A Phase 2, Open Label, 2 Cohort Study of INCB050465, a PI3Kd Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor, CITADEL 204 | No dispute reported | 06/30/2026 | 666498941 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $21,962.00 | 02/11/2019 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY INC | MONALEESA 3 A RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED STUDY OF RIBOCICLIB IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WHO HAVE RECEIVED NO OR ONLY ONE LINE | No dispute reported | 06/30/2026 | 640727611 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $94,395.74 | 02/08/2019 | Non-covered Recipient Entity CENTRAL COAST MEDICAL ONCOLOGY | RIBOCICLIB STANDARD ENDOCRINE THERAPY IN PATIENTS WITH HR HER2 EARLY BC AT HIGH AMP INTERMEDIATE RISK FOR RECURRENCE | No dispute reported | 06/30/2026 | 753935086 |
| Principal investigator 1 | Incyte Corporation | $18.00 | 02/05/2019 | Non-covered Recipient Entity CENTRAL COAST MEDICAL ONCOLOGY | PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES | No dispute reported | 06/30/2026 | 666475303 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $7,585.00 | 02/04/2019 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY US INC | ABT 199 GDC 0199 IN 1L DLBCL | No dispute reported | 06/30/2026 | 681059361 |
| Principal investigator 1 | PFIZER INC. | $100.00 | 01/31/2019 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY US INC | MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT PD0332991 PALBOCICLIB GOSERELIN IN WOMEN WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY | No dispute reported | 06/30/2026 | 671618683 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $5,545.00 | 01/30/2019 | Non-covered Recipient Entity CENTRAL COAST MEDICAL ONCOLOGY | TRINITI1 A PHASE I AND OR II SINGLE ARM OPEN LABEL STUDY OF RIBOCICLIB IN COMBINATION WITH EVEROLIMUS PLUS EXEMESTANE IN THE TREATMENT OF MEN AND POSTMENOPAUSAL WOMEN WITH HR PLUS HER2 LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON | No dispute reported | 06/30/2026 | 640712841 |
| Principal investigator 1 | Seattle Genetics, Inc. | $3,901.00 | 01/29/2019 | Non-covered Recipient Entity CENTRAL COAST MEDICAL ONCOLOGY | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | No dispute reported | 06/30/2026 | 678824771 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $45.91 | 01/28/2019 | Non-covered Recipient Entity Central Coast Medical Oncology Corporation | Adaptive Pan Malignancy Study for indications in which there is no approved immunomodulating therapy or BMS registration pathway | No dispute reported | 06/30/2026 | 639763649 |
| Principal investigator 1 | Eli Lilly and Company | $282.20 | 01/28/2019 | Non-covered Recipient Entity TRANSLATIONAL ONCOLOGY RESEARCH INTERNATIONAL INC | RANDOMIZED STUDY OF AM0010 IN COMBINATION WITH FOLFOX COMPARED TO FOLFOX ALONE AS SECOND-LINE TX IN PTS WITH META PANCREATIC CANCER THAT HAS PROGRESSED DURING OR FOLLOWING A FIRST-LINE GEMCITABINE CONTAINING REGIMEN | No dispute reported | 06/30/2026 | 654298943 |
| Principal investigator 1 | EMD Serono, Inc. | $36.00 | 01/18/2019 | Non-covered Recipient Entity UCLA TRIO US CAN CARE ASSOC MED GRP INC | EMR 100070-007 | No dispute reported | 06/30/2026 | 703030013 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $33,940.50 | 01/16/2019 | Non-covered Recipient Entity Translational Oncology Research International | An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies CheckMate 627 | No dispute reported | 06/30/2026 | 639763643 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $421.52 | 01/01/2019 | Non-covered Recipient Entity CENTRAL COAST MEDICAL ONCOLOGY | TWO ARM RANDOMIZED PHASE 3 STUDY IN HIGH RISK NSCLC COMPARING CANAKINUMAB VS PLACEBO IN ADJUVANT SETTING | No dispute reported | 06/30/2026 | 640712833 |